Clinical Trial Update: A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of BIND-014, a docetaxel nanoparticle formulation, as second-line therapy for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BIND-014 (docetaxel nanoparticle)

Snippet

Sponsor: BIND Therapeutics | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED